Compare LCTX & AVNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | AVNW |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.7M | 278.2M |
| IPO Year | 1996 | 2007 |
| Metric | LCTX | AVNW |
|---|---|---|
| Price | $1.12 | $21.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.25 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 991.0K | 114.2K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $14,556,000.00 | ★ $243,858,000.00 |
| Revenue This Year | $109.40 | $5.59 |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | ★ N/A | $73.86 |
| Revenue Growth | ★ 53.24 | 0.56 |
| 52 Week Low | $0.95 | $13.92 |
| 52 Week High | $2.09 | $27.02 |
| Indicator | LCTX | AVNW |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.25 |
| Support Level | N/A | $20.60 |
| Resistance Level | N/A | $22.95 |
| Average True Range (ATR) | 0.00 | 1.07 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 61.62 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.